



# Johnson & Johnson (JNJ)

Updated July 20<sup>th</sup>, 2023 by Nathan Parsh

## Key Metrics

<b>Current Price:</b>	\$168	<b>5 Year CAGR Estimate:</b>	10.2%	<b>Market Cap:</b>	\$412 billion
<b>Fair Value Price:</b>	\$183	<b>5 Year Growth Estimate:</b>	6.0%	<b>Ex-Dividend Date:</b>	08/23/23 <sup>1</sup>
<b>% Fair Value:</b>	92%	<b>5 Year Valuation Multiple Estimate:</b>	1.7%	<b>Dividend Payment Date:</b>	09/06/23 <sup>2</sup>
<b>Dividend Yield:</b>	2.8%	<b>5 Year Price Target</b>	\$245	<b>Years Of Dividend Growth:</b>	61
<b>Dividend Risk Score:</b>	A	<b>Retirement Suitability Score:</b>	A	<b>Rating:</b>	Buy

## Overview & Current Events

Johnson & Johnson is a diversified health care company and a leader in the area of pharmaceuticals and medical devices. Johnson & Johnson was founded in 1886 and employs more than 152,000 people around the world. The company is projected to generate approximately \$99 billion in revenue this year.

On January 4<sup>th</sup>, 2023, Kenvue filed to be listed as an independent company.

On April 18<sup>th</sup>, 2023, Johnson & Johnson announced that it was increasing its quarterly dividend 5.3% to \$1.19, extending the company's dividend growth streak to 61 consecutive years.

On May 4<sup>th</sup>, 2023, Kenvue, began trading on the New York Stock Exchange under the ticker symbol KVUE.

On July 20<sup>th</sup>, 2023, Johnson & Johnson announced results for the second quarter for the period ending June 30<sup>th</sup>, 2023. For the quarter, revenue grew 6.4% to \$25.5 billion, which was \$860 million more than expected. Adjusted earnings-per-share of \$2.80 compared favorably to \$2.59 in the prior year and was \$0.18 more than anticipated.

Excluding unfavorable currency exchange, revenue grew 7.5%. Pharmaceutical revenues grew 3.1% on a reported basis (up 7.2% excluding currency exchange). Infectious disease fell nearly 15% (-16.6%), mostly due to reduced Covid-19 vaccine revenue. Oncology was higher by 8.8% (+9.7%) as *Darzalex*, which treats multiple myeloma, continues to increase market share. *Imbruvica*, which treats lymphoma, still leads in market share, but has suffered declines due to competitive pressures. Immunology was up 1.9% (+2.6%) as market share gains in *Stelara*, which treats immune-mediated inflammatory diseases, continues to be offset by unfavorable patient mix and higher rebates. Consumer revenue improved 5.4% (+ 7.7%) as the lone declining business was Baby Care. MedTech was the best performing segment, with revenue growing 12.9% (+14.7%). Interventional Solutions improved more than 54% (+56.9%) as procedure recovery was excellent outside of the U.S. All other businesses were higher by a mid-single-digit percentage.

Johnson & Johnson offered revised guidance for 2023 as well. The company now expects revenue in a range of \$98.8 billion to \$99.8 billion for the year, up from \$97.9 billion to \$98.9 billion and \$96.9 billion to \$97.9 billion previously. Adjusted earnings-per-share is forecasted to be in a range of \$10.70 to \$10.80, up from \$10.60 to \$10.70 and \$10.45 to \$10.65 previously. We have updated our forecast accordingly.

## Growth on a Per-Share Basis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
<b>EPS</b>	\$5.52	\$5.70	\$5.48	\$5.93	\$7.30	\$8.18	\$8.68	\$8.03	\$9.80	\$10.15	<b>\$10.75</b>	<b>\$14.39</b>
<b>DPS</b>	\$2.59	\$2.76	\$2.95	\$3.15	\$3.32	\$3.54	\$3.80	\$4.04	\$4.19	\$4.45	<b>\$4.76</b>	<b>\$6.37</b>
<b>Shares<sup>3</sup></b>	2821	2783	2755	2707	2683	2650	2684	2669	2670	2661	<b>2626</b>	<b>2575</b>

Johnson & Johnson has grown earnings over the past 10 years at a rate of 7.0%. The company managed to grow earnings before, during and after the last recession, showing that the company's products are in demand regardless of market conditions. We expect earnings-per-share to grow at a rate of 6% per year through 2028 due to gains in revenue and

<sup>1</sup> Estimated ex-dividend date

<sup>2</sup> Estimated dividend payment date

<sup>3</sup> In millions of shares.

Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated July 20<sup>th</sup>, 2023 by Nathan Parsh

share repurchases. This is consistent with Johnson & Johnson's earnings growth composition in the past, however, most growth will come from revenue expansion as the buyback is good for a low-single-digit gain annually.

## Valuation Analysis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	Now	2028
Avg. P/E	15.6	17.7	18.2	19.1	23.9	23.7	15.6	18.2	17.5	17.4	15.6	17.0
Avg. Yld.	3.0%	2.7%	3.0%	2.8%	2.6%	2.7%	2.8%	2.7%	2.4%	2.5%	2.8%	2.6%

Shares of Johnson & Johnson are up \$6, or 3.7%, since our April 18<sup>th</sup>, 2023 update. Using the current share price and revised guidance for earnings-per-share for the year, Johnson & Johnson trades with a price-to-earnings ratio of 15.6, which is below our target price-to-earnings ratio of 17. Multiple expansion could add 1.7% to annual returns through 2028.

## Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
Payout	47%	48%	54%	53%	46%	43%	44%	50%	43%	44%	44%	44%

Johnson & Johnson has a reasonably low dividend payout ratio. This gives the company ample room to raise its dividend, even in a prolonged recession. One of Johnson & Johnson's key competitive advantages is the size and scale of its business. The company is a worldwide leader in a number of healthcare categories. Johnson & Johnson's diversification allows it to continue to grow even if one of the segments is underperforming. The upcoming planned separation of businesses should allow the faster growing segments should allow the company to unlock value for shareholders as the faster growing segments, Pharmaceutical and MedTech, could receive a higher multiple from the market.

## Final Thoughts & Recommendation

After second quarter earnings results, Johnson & Johnson is expected to offer a total annual return of 10.2% through 2028, down slightly from our prior forecast of 10.8%. Our projected return stems from a 6% earnings growth rate, a starting yield of 2.8%, and a small contribution from multiple expansion. Johnson & Johnson continues to post solid results. The company remains on track to divest its shares of the Consumer business by mid-to-late 2023 to focus on the faster growing Pharmaceutical and MedTech segments. We have raised our five-year price target \$3 to \$245 due to guidance for 2023 and continue to rate shares of Johnson & Johnson as a buy due to projected returns.

## Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated July 20<sup>th</sup>, 2023 by Nathan Parsh

## Income Statement Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
<b>Revenue</b>	71,312	74,331	70,074	71,890	76,450	81,581	82,059	82,584	93,775	94,943
<b>Gross Profit</b>	48,970	51,585	48,538	50,101	51,011	54,490	54,503	54,157	63,920	63,854
<b>Gross Margin</b>	68.7%	69.4%	69.3%	69.7%	66.7%	66.8%	66.4%	65.6%	68.2%	67.3%
<b>D&amp;A Exp.</b>	4,104	3,895	3,746	3,754	5,642	6,929	7,009	7,231	7,390	6,970
<b>Operating Profit</b>	18,957	21,137	18,289	20,891	18,897	21,175	20,970	19,733	23,647	23,703
<b>Operating Margin</b>	26.6%	28.4%	26.1%	29.1%	24.7%	26.0%	25.6%	23.9%	25.2%	25.0%
<b>Net Profit</b>	13,831	16,323	15,409	16,540	1,300	15,297	15,119	14,714	20,878	17,941
<b>Net Margin</b>	19.4%	22.0%	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	22.3%	18.9%
<b>Free Cash Flow</b>	13,819	14,996	16,106	15,541	17,777	18,531	19,918	20,189	19,758	17,185
<b>Income Tax</b>	1,640	4,240	3,787	3,263	16,373	2,702	2,209	1,783	1,898	3,784

## Balance Sheet Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
<b>Total Assets</b>	132683	130358	133411	141208	157303	152954	157728	174894	182018	187378
<b>Cash &amp; Equivalents</b>	20927	14523	13732	18972	17824	18107	17305	13985	14487	14127
<b>Acc. Receivable</b>	11713	10985	10734	11699	13490	14098	14481	13576	15283	16160
<b>Inventories</b>	7878	8184	8053	8144	8765	8599	9020	9344	10387	12483
<b>Goodwill &amp; Int.</b>	50745	49054	47393	49681	85134	78064	81282	89795	81638	93556
<b>Total Liabilities</b>	58630	60606	62261	70790	97143	93202	98257	111616	107995	110574
<b>Accounts Payable</b>	6266	7633	6668	6918	7310	7537	8544	9505	11055	11703
<b>Long-Term Debt</b>	18180	18760	19861	27126	34581	30480	27696	35266	33751	39659
<b>Total Equity</b>	74053	69752	71150	70418	60160	59752	59471	63278	74023	76804
<b>LTD/E Ratio</b>	0.25	0.27	0.28	0.39	0.57	0.51	0.47	0.56	0.46	0.52

## Profitability & Per Share Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
<b>Return on Assets</b>	10.9%	12.4%	11.7%	12.0%	0.9%	9.9%	9.7%	8.8%	11.7%	9.7%
<b>Return on Equity</b>	19.9%	22.7%	21.9%	23.4%	2.0%	25.5%	25.4%	24.0%	30.4%	23.8%
<b>ROIC</b>	16.0%	18.1%	17.2%	17.5%	1.4%	16.5%	17.0%	15.8%	20.2%	16.0%
<b>Shares Out.</b>	2821	2783	2755	2707	2683	2650	2684	2669	2667	2661
<b>Revenue/Share</b>	24.79	25.95	24.91	25.78	27.85	29.90	30.57	30.92	35.07	35.64
<b>FCF/Share</b>	4.80	5.24	5.73	5.57	6.48	6.79	7.42	7.56	7.39	6.45

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.